FDA extends review date for Celgene cancer drug

Celgene said it expects to submit in November its application for Revlimid to treat previously treated patients with relapsed multiple myeloma.

Last week, Celgene said it expected a suspended trial of the drug to resume within weeks, after the trial design is changed to ensure all patients receive aspirin to reduce the chance of developing blood clots.